April 27, 2026 — On April 2, 2026, President Trump issued a Proclamation invoking Section 232 of the Trade Expansion Act of 1962 to impose sweeping tariffs on imports of patented pharmaceuticals, biologics, and associated ingredients into the United States. Beginning July 31, 2026, a 100% tariff will apply to patented drug products listed in the FDA's Orange Book and Purple Book, along with their active pharmaceutical ingredients (APIs) and key starting materials. This marks the most significant trade policy intervention in the pharmaceutical sector in decades, with far-reaching implications for API suppliers, intermediate manufacturers, and finished dosage form producers across the global supply chain.
The Section 232 tariffs establish a multi-tiered duty structure that differentiates products by patent status, country of origin, and corporate compliance posture:
Standard 100% rate: Applies to patented pharmaceuticals, their APIs, and key starting materials imported from most countries. This replaces existing tariff rates and takes effect July 31, 2026 for most importers.
15% reduced rate: Products from Japan, EU member states, South Korea, Switzerland, and Liechtenstein qualify for a significantly reduced 15% tariff, reflecting existing bilateral trade agreements.
20% onshoring rate: Companies with approved U.S. manufacturing onshoring plans pay only a 20% additional tariff until April 2, 2030, creating a powerful incentive for domestic capacity investment.
Full exemption: Companies that both establish U.S. onshoring plans and enter into Most Favored Nation (MFN) pricing agreements with the Department of Health and Human Services (HHS) are fully exempt from additional tariffs until January 20, 2029.
In a critical carve-out for the generic pharmaceutical industry, the Proclamation explicitly exempts generic drugs, biosimilars, and their associated APIs and key starting materials from Section 232 tariffs. This is a significant relief for generic drug manufacturers and their API suppliers, who collectively supply over 90% of prescriptions dispensed in the United States.
Additional exemptions apply to:
U.S.-origin pharmaceutical products, APIs, and key starting materials
Orphan drug-designated products under the Orphan Drug Act
Nuclear medicines, plasma-derived therapies, fertility treatments, and cell and gene therapies
Antibody-drug conjugates (ADCs) — a notable exemption given the rapid growth of the ADC pipeline
Medical countermeasures related to CBRN threats
Prototypes for development, testing, and quality control purposes
For API and intermediate manufacturers, the Section 232 tariffs represent both a challenge and a strategic opportunity:
The tariff framework creates a powerful economic incentive for pharmaceutical companies to onshore API and finished product manufacturing to the United States. Companies with approved onshoring plans pay only 20% versus the standard 100% rate — a margin differential that fundamentally changes the economics of domestic versus overseas production. API suppliers with existing or planned U.S. manufacturing capacity stand to capture significant new business as brand-name pharmaceutical companies race to qualify for reduced tariff rates.
Pharmaceutical companies will need to rapidly assess and restructure their global supply chains. For APIs currently sourced from countries subject to the full 100% rate, companies face a stark choice: absorb the tariff cost, pass it through to consumers, or shift sourcing to exempt or reduced-rate jurisdictions. This creates immediate demand for API suppliers in tariff-favorable geographies, particularly those with U.S. manufacturing operations or facilities in EU, Japan, or South Korea.
The explicit exemption of generics and biosimilars from Section 232 tariffs is a significant positive for the generic pharmaceutical supply chain. As patented drugs face higher landed costs due to tariffs, the price advantage of generic alternatives widens, potentially accelerating generic substitution rates and increasing demand for generic APIs. Suppliers of APIs for molecules approaching patent expiry should anticipate accelerated demand as the tariff-driven cost gap incentivizes earlier generic entry.
With the July 31, 2026 effective date approaching rapidly, pharmaceutical companies face a tight compliance window. Named companies listed in Annex III have until September 29, 2026. Companies must classify their products under the new HTSUS provisions, assess exemption eligibility, and evaluate onshoring options within months. For API suppliers, this means urgent engagement with customers on supply chain restructuring, qualification of alternative manufacturing sites, and documentation of product origin and patent status.
The tiered tariff structure creates distinct competitive dynamics by geography:
India: Indian API and finished drug exporters face the full 100% rate unless their products are exempt (generics/biosimilars) or qualify for onshoring incentives. India's pharmaceutical exports to the U.S. exceeded $8 billion in 2025, with significant volumes of both generic APIs and patented finished dosage forms. Indian CDMOs may see accelerated demand for U.S. facility investments.
China: Chinese API manufacturers supplying patented drug ingredients face the full 100% tariff. However, Chinese generic API exports remain exempt. The tariffs may accelerate the ongoing diversification of pharmaceutical supply chains away from China for patented drug ingredients.
EU and Japan: The 15% reduced rate provides a significant competitive advantage for European and Japanese API and pharmaceutical manufacturers relative to other exporting nations. This may redirect sourcing patterns and strengthen transatlantic and transpacific pharmaceutical trade relationships.
In this rapidly evolving trade environment, API suppliers, intermediate manufacturers, and specialty chemical producers should take the following steps:
Product classification: Immediately assess whether your products fall under tariffed HTSUS provisions (Annex I) or exempt codes (Annex IV).
Customer engagement: Proactively communicate with pharmaceutical customers about supply chain options, alternative manufacturing sites, and product origin documentation.
U.S. manufacturing assessment: Evaluate the economics of establishing or expanding U.S. API manufacturing operations to capture the onshoring rate advantage.
Portfolio optimization: Prioritize generic API and biosimilar development pipelines, which are explicitly exempt from Section 232 tariffs.
Regulatory monitoring: Closely track Commerce Department rulemaking on onshoring plan approval processes and MFN pricing agreement requirements.
The Section 232 pharmaceutical tariffs represent a structural transformation of the global pharmaceutical trade landscape. For API suppliers and CDMOs, the message is clear: the economics of pharmaceutical manufacturing are being fundamentally rewritten. Companies that move quickly to establish U.S. manufacturing capacity, strengthen relationships with tariff-advantaged customers, and optimize their product portfolios for the new trade framework will be best positioned to thrive in this transformed environment. The window for strategic action is narrow — with the first tariffs taking effect July 31, 2026, the time to act is now.
